Allergy-immunology. New therapies for acute attacks in hereditary angioedema

Hereditary angioedema is a disease which develops as a result of a deficiency or dysfonction of C1-inhibitor, a key regulator of the complement, coagulation and contact cascades, resulting among others in excessive release of bradykinin. This disease mortality rate is high in absence of immediate an...

Full description

Saved in:
Bibliographic Details
Published inRevue médicale suisse Vol. 7; no. 278; pp. 103 - 105
Main Author Leimgruber, Annette
Format Journal Article
LanguageFrench
Published Switzerland 19.01.2011
Subjects
Adrenergic beta-Antagonists - therapeutic use
Angioedemas, Hereditary - drug therapy
Bradykinin - analogs & derivatives
Bradykinin - therapeutic use
Complement C1 Inhibitor Protein - therapeutic use
Complement Inactivating Agents - therapeutic use
Humans
Online AccessGet full text

Cover

More Information
Summary:Hereditary angioedema is a disease which develops as a result of a deficiency or dysfonction of C1-inhibitor, a key regulator of the complement, coagulation and contact cascades, resulting among others in excessive release of bradykinin. This disease mortality rate is high in absence of immediate and effective treatment, in particular in presence of acute attacks of the upper respiratory tract (laryngeal edema). Until now only administration of a purified C1-inhibitor extract was effective against these symptoms. This paper aims to synthesise essentials knowledge concerning news drugs, in particular icatibant, a selective bradykinin B2- receptor antagonist whose use should be widened to the treatment of angioedema with ACE-inhibitors intolerance.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1660-9379